Related Experiment Videos
Consensus guidelines on anti-cardiolipin antibody testing and reporting
Richard C W Wong1, David Gillis, Stephen Adelstein
1Division of Immunology, Queensland Health Pathology Services, Princess Alexandra and Royal Brisbane Hospitals, Qld., Australia. richard_wong@health.qld.gov.au
Pathology
|February 6, 2004
Summary
Consensus guidelines for anti-cardiolipin antibody (aCL) testing standardize laboratory practices. These recommendations aim to reduce variation in aCL assay performance and reporting for improved diagnostic accuracy.
Area of Science:
- Clinical Immunology
- Laboratory Medicine
Background:
- Anti-cardiolipin antibodies (aCL) are crucial biomarkers for anti-phospholipid antibody syndrome (APS).
- Laboratory variation in aCL testing can impact diagnostic accuracy and patient management.
Framework:
- Development of consensus guidelines to standardize aCL testing and reporting.
- Recommendations cover assay performance, specimen handling, controls, calibrators, and result interpretation.
Implementation:
- Guidelines address specific aspects including isotype testing, specimen type, assay precision, and cut-off values.
- Inclusion of recommendations for rheumatoid factor and IgM aCL testing.
- Emphasis on standardized reporting and interpretative comments.
Implications:
- Minimizing laboratory variation in aCL testing.
- Enhancing the reliability and consistency of aCL assay results.
- Improving the diagnosis and management of conditions associated with aCL.